Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page . P2 v" p5 |! A" P6 V |" L
8 L9 {2 l& t. x* N% R+ j. C h* [5 D/ U" F; b' \6 F) \
Sub-category:' [8 T" a# n2 E& @$ @. e+ f* r: O: N; D
Molecular Targets
* Y+ |% e% d+ I3 Z5 t* E- n% O( P6 C( k( v
h& V! \+ P) s2 O" \9 e6 J. MCategory:/ d# L H, m; y/ p- Y6 I% I
Tumor Biology - V, r! W* g% A2 O9 s
+ q% Z" u! m" {9 k+ n ]2 A# c: @9 @1 K" l" ~- j0 W T5 T6 N3 ^1 z5 A
Meeting:
. G; @* |; g% R0 w O5 [4 n2011 ASCO Annual Meeting
1 w' ?4 C; e0 {, z) C
" c1 `; ~8 l& i: ^2 B
+ Z: h& T1 m4 d, m' wSession Type and Session Title:
6 F5 x% K1 _% K" nPoster Discussion Session, Tumor Biology
% z9 M1 p( W8 F F3 H
0 N8 I8 o- h+ u7 W/ f8 p* y5 q2 k, B" F- q' b+ S1 A
Abstract No:9 O/ E* b3 M/ [* E4 |
10517 1 Z1 a" b# z% x4 ^/ t4 K
9 g Z& n! e; N \; q) g: d: X. c3 d
2 h. D, q0 C% a' V* bCitation:
4 |* s5 J u( {2 H9 ?J Clin Oncol 29: 2011 (suppl; abstr 10517)
" H) E; w$ [6 j, e, W A8 }9 Y$ g( C0 q0 l: E% u
, d+ E' A3 g5 u
Author(s): B- T, L" n% m5 L5 Y
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China $ ~: L; \" o% [" j! U/ `
4 T( C0 I( ^' i, o/ P
1 ?5 H; P+ P4 v0 F- P( [
# a9 t7 M2 d" q5 h* A: C+ lAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
' c7 ]$ \' C( c2 E' l$ R. K7 n) B* {+ h K" |
Abstract Disclosures. f- T& L' q9 }" R1 c$ y: S
; C( R4 T* d; p$ f4 A; ?Abstract:1 p, [% Q' [8 \3 D$ W- Z
0 F6 q2 `% N! V( ^6 s! q
; E; T$ d. v, G$ K- y+ ]Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
1 T1 v& P }2 o
. m0 c( I% s" A. q1 o& H / _# f; Q4 X# _7 B, i; Q' u
|